Moreover, the JAK2 haplotype, repeatedly confirmed as a strong host genetic predisposition factor for MPN in GWAS, has been identified as a biomarker of disease outcome in PMF by Tefferi’s group. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.